Aptamer Sciences Inc. (291650.KQ)
- Previous Close
2,665.00 - Open
2,675.00 - Bid --
- Ask --
- Day's Range
2,665.00 - 2,790.00 - 52 Week Range
2,400.00 - 6,080.00 - Volume
32,190 - Avg. Volume
186,318 - Market Cap (intraday)
46.696B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 10, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aptamer Sciences, Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's aptamer platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics. It offers AlloMAp and BiFAp platform programs for therapeutics; and diagnosis kits for lung and pancreatic cancer, as well as in-vitro diagnostic kits for the early diagnosis of lung cancer. Aptamer Sciences, Inc. was founded in 2011 and is headquartered in Seongnam, South Korea.
www.aptsci.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 291650.KQ
Performance Overview: 291650.KQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 291650.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 291650.KQ
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.52%
Return on Equity (ttm)
-60.85%
Revenue (ttm)
243.19M
Net Income Avi to Common (ttm)
-13.6B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
23.79B
Total Debt/Equity (mrq)
53.50%
Levered Free Cash Flow (ttm)
-2.46B
Company Insights: 291650.KQ
291650.KQ does not have Company Insights